Rebecca E O'connor

发表

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

Malina A. Bakowski, Chunlong Ma, Jun Wang, 2021, Nature Communications.

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19

Malina A. Bakowski, R. Obach, Chunlong Ma, 2020, bioRxiv.

Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor

M. Ehlers, P. Tierney, R. Kozak, 2018, Nature Communications.

Discovery of Selective M4 Muscarinic Acetylcholine Receptor Agonists with Novel Carbamate Isosteres.

R. Kozak, Qingyi Yang, C. Butler, 2019, ACS medicinal chemistry letters.

In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.

D. Scott, D. Hargrove, R. L. Dow, 2010, Biochemical and biophysical research communications.

New bicyclic cannabinoid receptor-1 (CB1-R) antagonists.

D. Scott, P. Iredale, S. Sakya, 2006, Bioorganic & medicinal chemistry letters.

Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) Receptor Antagonist

D. Scott, P. Iredale, Xingrong Liu, 2010, BMC pharmacology.

Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity.

D. Scott, P. Iredale, C. Nduaka, 2009, Journal of medicinal chemistry.

Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline.

C. Thorn, J. Edgerton, Rebecca E O'connor, 2018, ACS chemical neuroscience.

Discovery and Lead Optimization of Atropisomer D1 Agonists with Reduced Desensitization.

R. Kozak, David L. Gray, B. Rai, 2018, Journal of medicinal chemistry.

Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.

K. Fennell, J. Pandit, F. Menniti, 2011, Journal of medicinal chemistry.

Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.

Spiros Liras, Anne W. Schmidt, J. Pandit, 2009, Journal of medicinal chemistry.

Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents.

D. Scott, P. Iredale, R. L. Dow, 2012, ACS medicinal chemistry letters.

A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CLpro Inhibitor PF-00835231 as a Potential New Treatment for COVID-19

Kelly V. Ruggles, K. Ruggles, Sergei B Koralov, 2021, Journal of Virology.

A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19

K. Ruggles, Sergei B Koralov, C. Steppan, 2020, bioRxiv.

Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.

Laura McDowell, Scot Mente, Mihaly Hajos, 2017, Journal of medicinal chemistry.

Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist.

Margaret S. Landis, D. Scott, P. Iredale, 2009, Journal of medicinal chemistry.

Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite Loss.

Jeonifer M. Garren, Martin R. M. Koos, J. Fortin, 2023, Journal of medicinal chemistry.

Discovery and pharmacological characterization of a selective delta opiate receptor antagonist (CP-646,777)

Anne W. Schmidt, S. Liras, Ernesto Callegari, 2011 .

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate.

J. Pandit, W. Hoffman, M. Hajós, 2018, Journal of medicinal chemistry.

Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.

Laura McDowell, Spiros Liras, Mihaly Hajos, 2012, Journal of medicinal chemistry.

Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor

M. Ehlers, P. Tierney, R. Kozak, 2018, Nature Communications.

Comparative study of a 3CLpro inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models

C. Steppan, A. Anderson, Adil Mohamed, 2020, bioRxiv.

Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects.

B. L. Kormos, C. J. Schmidt, Travis T Wager, 2017, ACS chemical neuroscience.

Late-Stage Microsomal Oxidation Reduces Drug–Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189

G. S. Walker, A. Stepan, R. Obach, 2018, ACS Medicinal Chemistry Letters.